De-escalation and escalation of treatment of patients with HER2-positive breast cancer
On March 15, 2017, the 15th St. Gallen International Breast Cancer Conference (Vienna) examined controversial clinical issues with the goal of reaching agreement among the 50 most influential panel world leaders. Also, the results of randomized trials were examined in order to narrow or, conversely, expand the standards for local and systemic treatment. The introduction of trastuzumab in combination chemotherapy has significantly improved the results of treatment of HER2-positive breast cancer. Double inhibition of HER2 appears to be a promising strategy to improve the frequency of pCR and the survival rates in patients with breast cancer.